Across TCGA pan-cancer cohorts, HYAL6P Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HYAL6P data layer compared with 15 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher HYAL6P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HYAL6P expression acts as an unfavorable survival marker.
ESCA and UCEC are the cancer types where HYAL6P Mutation most reproducibly stratifies survival.